Published in Neuromodulation on June 01, 2012
Mesoporous silica-supported lipid bilayers (protocells) for DNA cargo delivery to the spinal cord. J Control Release (2013) 1.43
Neuropathic pain and cytokines: current perspectives. J Pain Res (2013) 1.26
Monocytes/Macrophages control resolution of transient inflammatory pain. J Pain (2014) 0.87
Modulating the delicate glial-neuronal interactions in neuropathic pain: promises and potential caveats. Neurosci Biobehav Rev (2014) 0.86
Improvement of spinal non-viral IL-10 gene delivery by D-mannose as a transgene adjuvant to control chronic neuropathic pain. J Neuroinflammation (2014) 0.81
Optogenetic and chemogenetic strategies for sustained inhibition of pain. Sci Rep (2016) 0.80
Preclinical toxicity evaluation of AAV for pain: evidence from human AAV studies and from the pharmacology of analgesic drugs. Mol Pain (2014) 0.80
The search for novel analgesics: targets and mechanisms. F1000Prime Rep (2015) 0.79
The neuroprotective effect exerted by oligodendroglial progenitors on ischemically impaired hippocampal cells. Mol Neurobiol (2013) 0.78
High cerebrospinal fluid levels of interleukin-10 attained by AAV in dogs. Gene Ther (2014) 0.76
Spinal Cord T-Cell Infiltration in the Rat Spared Nerve Injury Model: A Time Course Study. Int J Mol Sci (2016) 0.76
Anti-nociceptive and anti-inflammatory actions of sulforaphane in chronic constriction injury-induced neuropathic pain mice. Inflammopharmacology (2017) 0.76
HDAC6 inhibition effectively reverses chemotherapy-induced peripheral neuropathy. Pain (2017) 0.75
Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol (2001) 25.63
A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain (1988) 15.15
Microglia: a sensor for pathological events in the CNS. Trends Neurosci (1996) 12.00
Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity (2011) 11.15
CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol (2001) 9.19
Persistent postsurgical pain: risk factors and prevention. Lancet (2006) 8.46
TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol (2004) 8.06
Design and development of polymers for gene delivery. Nat Rev Drug Discov (2005) 6.79
P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury. Nature (2003) 6.04
Pathological and protective roles of glia in chronic pain. Nat Rev Neurosci (2009) 5.53
The neuropathic pain triad: neurons, immune cells and glia. Nat Neurosci (2007) 5.38
Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. J Immunol (2004) 5.15
Neuropathic pain: a maladaptive response of the nervous system to damage. Annu Rev Neurosci (2009) 5.00
GLIA: listening and talking to the synapse. Nat Rev Neurosci (2001) 4.67
p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia. Neuron (2002) 4.27
Interleukin-10: new perspectives on an old cytokine. Immunol Rev (2008) 3.94
Prevalence of chronic pain with neuropathic characteristics in the general population. Pain (2007) 3.72
Uptake pathways and subsequent intracellular trafficking in nonviral gene delivery. Pharmacol Rev (2006) 3.71
The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. J Pain (2006) 3.67
Nociceptors--noxious stimulus detectors. Neuron (2007) 3.23
The tripartite synapse: roles for gliotransmission in health and disease. Trends Mol Med (2007) 3.05
Opioids in the management of chronic non-cancer pain: an update of American Society of the Interventional Pain Physicians' (ASIPP) Guidelines. Pain Physician (2008) 2.76
p38 MAPK, microglial signaling, and neuropathic pain. Mol Pain (2007) 2.72
Macrophages ingest and are activated by bacterial DNA. J Immunol (1996) 2.64
Glial-cytokine-neuronal interactions underlying the mechanisms of persistent pain. J Neurosci (2007) 2.44
Immune and glial cell factors as pain mediators and modulators. Exp Neurol (2005) 2.30
Comprehensive review of epidemiology, scope, and impact of spinal pain. Pain Physician (2009) 2.29
Expression of CCR2 in both resident and bone marrow-derived microglia plays a critical role in neuropathic pain. J Neurosci (2007) 2.28
The molecular dynamics of pain control. Nat Rev Neurosci (2001) 2.21
Spatial and temporal relationship between monocyte chemoattractant protein-1 expression and spinal glial activation following peripheral nerve injury. J Neurochem (2006) 2.14
The immunobiology of the TLR9 subfamily. Trends Immunol (2004) 2.11
Current challenges in glia-pain biology. Neuron (2009) 2.11
The neuronal chemokine CX3CL1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system. FASEB J (2006) 2.04
Identification and functional characterization of a second chain of the interleukin-10 receptor complex. EMBO J (1997) 2.03
Neuron-glia crosstalk gets serious: role in pain hypersensitivity. Curr Opin Anaesthesiol (2008) 1.99
Neurotransmitter receptors on microglia. Trends Neurosci (2007) 1.84
Chemokines: a new class of neuromodulator? Nat Rev Neurosci (2007) 1.76
Controlling pathological pain by adenovirally driven spinal production of the anti-inflammatory cytokine, interleukin-10. Eur J Neurosci (2005) 1.73
Chemokines in the CNS: plurifunctional mediators in diverse states. Trends Neurosci (1999) 1.73
Chemokines: integrators of pain and inflammation. Nat Rev Drug Discov (2005) 1.68
Intrathecal interleukin-10 gene therapy attenuates paclitaxel-induced mechanical allodynia and proinflammatory cytokine expression in dorsal root ganglia in rats. Brain Behav Immun (2006) 1.67
Controlling neuropathic pain by adeno-associated virus driven production of the anti-inflammatory cytokine, interleukin-10. Mol Pain (2005) 1.66
Repeated intrathecal injections of plasmid DNA encoding interleukin-10 produce prolonged reversal of neuropathic pain. Pain (2006) 1.66
Reduced levels of antiinflammatory cytokines in patients with chronic widespread pain. Arthritis Rheum (2006) 1.64
Systemically administered interleukin-10 reduces tumor necrosis factor-alpha production and significantly improves functional recovery following traumatic spinal cord injury in rats. J Neurotrauma (1999) 1.55
Immunomodulatory effects of probiotic bacteria DNA: IL-1 and IL-10 response in human peripheral blood mononuclear cells. FEMS Immunol Med Microbiol (2003) 1.51
Antinociceptive effect of a genomic herpes simplex virus-based vector expressing human proenkephalin in rat dorsal root ganglion. Gene Ther (2001) 1.41
Changes in cerebrospinal fluid levels of pro-inflammatory cytokines in CRPS. Pain (2005) 1.38
Expression patterns of IL-10 ligand and receptor gene families provide leads for biological characterization. Int Immunopharmacol (2004) 1.38
Contribution of the activation of satellite glia in sensory ganglia to pathological pain. Neurosci Biobehav Rev (2009) 1.36
HSV-mediated expression of interleukin-4 in dorsal root ganglion neurons reduces neuropathic pain. Mol Pain (2006) 1.32
Selective increase of tumour necrosis factor-alpha in injured and spared myelinated primary afferents after chronic constrictive injury of rat sciatic nerve. Eur J Neurosci (2003) 1.32
Peripheral nerve injury alters blood-spinal cord barrier functional and molecular integrity through a selective inflammatory pathway. J Neurosci (2011) 1.31
Cytokine involvement in dynorphin-induced allodynia. Pain (2000) 1.29
Effects of interleukin-10 (IL-10) on pain behavior and gene expression following excitotoxic spinal cord injury in the rat. Exp Neurol (2001) 1.29
IL-10 directly protects cortical neurons by activating PI-3 kinase and STAT-3 pathways. Brain Res (2010) 1.24
HSV-mediated transfer of interleukin-10 reduces inflammatory pain through modulation of membrane tumor necrosis factor alpha in spinal cord microglia. Gene Ther (2007) 1.22
Cutaneous transfection and immune responses to intradermal nucleic acid vaccination are significantly enhanced by in vivo electropermeabilization. Mol Ther (2001) 1.22
Intrathecal polymer-based interleukin-10 gene delivery for neuropathic pain. Neuron Glia Biol (2006) 1.18
Accessing the therapeutic potential of immunostimulatory nucleic acids. Curr Opin Immunol (2008) 1.18
IL-10 promotes neuronal survival following spinal cord injury. Exp Neurol (2009) 1.16
Interleukin-10 prevents glutamate-mediated cerebellar granule cell death by blocking caspase-3-like activity. J Neurosci (2001) 1.15
Macrophages and dendritic cells in the rat meninges and choroid plexus: three-dimensional localisation by environmental scanning electron microscopy and confocal microscopy. Cell Tissue Res (2003) 1.15
Interleukin-10 provides direct trophic support to neurons. J Neurochem (2009) 1.14
Bilateral changes of TNF-alpha and IL-10 protein in the lumbar and cervical dorsal root ganglia following a unilateral chronic constriction injury of the sciatic nerve. J Neuroinflammation (2010) 1.14
Activation of P2X7 receptors in glial satellite cells reduces pain through downregulation of P2X3 receptors in nociceptive neurons. Proc Natl Acad Sci U S A (2008) 1.13
Full house: 12 receptors for 27 cytokines. Int Immunopharmacol (2004) 1.11
Neuroprotective effects of interleukin-10 following excitotoxic spinal cord injury. Exp Neurol (1999) 1.10
Cellular localization and expression patterns of interleukin-10, interleukin-4, and their receptors in multiple sclerosis lesions. Glia (2002) 1.10
Multiple sclerosis: cytokine receptors on oligodendrocytes predict innate regulation. Ann Neurol (2004) 1.10
Interleukin-10 receptor signaling through STAT-3 regulates the apoptosis of retinal ganglion cells in response to stress. Invest Ophthalmol Vis Sci (2003) 1.10
Differential involvement of trigeminal transition zone and laminated subnucleus caudalis in orofacial deep and cutaneous hyperalgesia: the effects of interleukin-10 and glial inhibitors. Mol Pain (2009) 1.08
The extent of cytokine induction in peripheral nerve lesions depends on the mode of injury and NMDA receptor signaling. J Neuroimmunol (2004) 1.08
Anti-inflammatory cytokine gene therapy decreases sensory and motor dysfunction in experimental Multiple Sclerosis: MOG-EAE behavioral and anatomical symptom treatment with cytokine gene therapy. Brain Behav Immun (2008) 1.05
Contralateral cytokine gene induction after peripheral nerve lesions: dependence on the mode of injury and NMDA receptor signaling. Brain Res Mol Brain Res (2005) 1.01
Role of glia in orofacial pain. Neuroscientist (2011) 1.01
Contribution of Toll-like receptor 9 signaling to the acute inflammatory response to nonviral vectors. Mol Ther (2004) 1.00
The effects of endogenous interleukin-10 on gray matter damage and the development of pain behaviors following excitotoxic spinal cord injury in the mouse. Neuroscience (2004) 1.00
Amelioration of chronic neuropathic pain after partial nerve injury by adeno-associated viral (AAV) vector-mediated over-expression of BDNF in the rat spinal cord. Gene Ther (2002) 0.99
Neuronal soma-satellite glial cell interactions in sensory ganglia and the participation of purinergic receptors. Neuron Glia Biol (2010) 0.96
Spinal microglial expression and mechanical hypersensitivity in a postoperative pain model: comparison with a neuropathic pain model. Anesthesiology (2009) 0.95
Regional and temporal expression patterns of interleukin-10, interleukin-10 receptor and adhesion molecules in the rat spinal cord during chronic relapsing EAE. J Neuroimmunol (2003) 0.94
Interleukin-2 gene therapy of chronic neuropathic pain. Neuroscience (2002) 0.93
Immunological priming potentiates non-viral anti-inflammatory gene therapy treatment of neuropathic pain. Gene Ther (2009) 0.93
Expression and contribution of satellite glial cells purinoceptors to pain transmission in sensory ganglia: an update. Neuron Glia Biol (2010) 0.93
Leptomeningeal cells activate microglia and astrocytes to induce IL-10 production by releasing pro-inflammatory cytokines during systemic inflammation. J Neuroimmunol (2005) 0.92
Specific and non-specific phagocytosis of ligand-grafted PLGA microspheres by macrophages. Eur J Pharm Sci (2008) 0.91
Contralateral non-operated nerve to transected rat sciatic nerve shows increased expression of IL-1beta, TGF-beta1, TNF-alpha, and IL-10. J Neuroimmunol (2002) 0.91
Evidence for a role of endocannabinoids, astrocytes and p38 phosphorylation in the resolution of postoperative pain. PLoS One (2010) 0.91
Modifying the proliferative state of target cells to control DNA expression and identifying cell types transfected in vivo. Mol Ther (2007) 0.89
Release of plasmid DNA-encoding IL-10 from PLGA microparticles facilitates long-term reversal of neuropathic pain following a single intrathecal administration. Pharm Res (2010) 0.89
Effects of agmatine, interleukin-10, and cyclosporin on spontaneous pain behavior after excitotoxic spinal cord injury in rats. J Pain (2003) 0.88
Intrathecal injection of naked plasmid DNA provides long-term expression of secreted proteins. Mol Ther (2008) 0.88
Reducing the immunostimulatory activity of CpG-containing plasmid DNA vectors for non-viral gene therapy. Expert Opin Drug Deliv (2004) 0.87
Interleukin-10 and interleukin-10 receptor-I are upregulated in glial cells after an excitotoxic injury to the postnatal rat brain. J Neuropathol Exp Neurol (2009) 0.86
Cellular components of the immune barrier in the spinal meninges and dorsal root ganglia of the normal rat: immunohistochemical (MHC class II) and electron-microscopic observations. Cell Tissue Res (1993) 0.86
Gene therapy applications for the treatment of neuropathic pain. Expert Rev Neurother (2007) 0.86
Versatility of biodegradable poly(D,L-lactic-co-glycolic acid) microspheres for plasmid DNA delivery. Eur J Pharm Biopharm (2006) 0.86
Intrathecal polymer-based interleukin-10 gene delivery for neuropathic pain. Neuron Glia Biol (2006) 1.18
Environmental cues to guide stem cell fate decision for tissue engineering applications. Expert Opin Biol Ther (2006) 0.97
Effect of macromer weight percent on neural cell growth in 2D and 3D nondegradable PEG hydrogel culture. J Biomed Mater Res A (2010) 0.96
BDNF-treated retinal progenitor sheets transplanted to degenerate rats: improved restoration of visual function. Exp Eye Res (2007) 0.90
Selective beta-cell differentiation of dissociated embryonic pancreatic precursor cells cultured in synthetic polyethylene glycol hydrogels. Tissue Eng Part A (2009) 0.89
Release of plasmid DNA-encoding IL-10 from PLGA microparticles facilitates long-term reversal of neuropathic pain following a single intrathecal administration. Pharm Res (2010) 0.89
PEGylation of interleukin-10 for the mitigation of enhanced pain states. J Biomed Mater Res A (2010) 0.88
Impact of lactic acid on cell proliferation and free radical-induced cell death in monolayer cultures of neural precursor cells. Biotechnol Bioeng (2009) 0.87
PEGylation of brain-derived neurotrophic factor for preserved biological activity and enhanced spinal cord distribution. J Biomed Mater Res A (2009) 0.85
Entrapped collagen type 1 promotes differentiation of embryonic pancreatic precursor cells into glucose-responsive beta-cells when cultured in three-dimensional PEG hydrogels. Tissue Eng Part A (2009) 0.85
Trophic factors GDNF and BDNF improve function of retinal sheet transplants. Exp Eye Res (2010) 0.84
The administration of BDNF and GDNF to the brain via PLGA microparticles patterned within a degradable PEG-based hydrogel: Protein distribution and the glial response. J Biomed Mater Res A (2011) 0.82
Impact of degradable macromer content in a poly(ethylene glycol) hydrogel on neural cell metabolic activity, redox state, proliferation, and differentiation. Tissue Eng Part A (2010) 0.81
Central nervous system delivery of large molecules: challenges and new frontiers for intrathecally administered therapeutics. Expert Opin Drug Deliv (2010) 0.80
A novel composite construct increases the vascularization potential of PEG hydrogels through the incorporation of large fibrin ribbons. J Biomed Mater Res A (2010) 0.79
Tissue engineering approaches to cell-based type 1 diabetes therapy. Tissue Eng Part B Rev (2014) 0.77
Inhibition of gamma-secretase activity promotes differentiation of embryonic pancreatic precursor cells into functional islet-like clusters in poly(ethylene glycol) hydrogel culture. Tissue Eng Part A (2010) 0.76